Could a diabetes drug help breast cancer survivors lose weight?
NCT ID NCT07257484
First seen Jun 25, 2026 · Last updated Jul 23, 2026 · Updated 3 times
Summary
This study tests whether tirzepatide, a drug used for diabetes and weight loss, is practical and acceptable for postmenopausal women who have had hormone receptor-positive breast cancer and are obese. Thirty participants will take the drug weekly for 24 weeks, with monthly check-ins to monitor progress and safety. The goal is to see if it helps with weight loss and overall health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tirzepatide
- What this could lead to
- If successful, this could show that tirzepatide is a practical option for weight management and better health in breast cancer survivors.
- What could go wrong
- This is a small, early-phase trial with only 30 participants, so results may not apply widely. Side effects from tirzepatide are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Weill Cornell Medicine
RECRUITINGNew York, New York, 10021, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?